PDCD1 and telomere syndrome: In an open-label multicenter phase 2 trial to evaluate the efficacy of nivolumab (anti-PD-1 antibody) in 21 Japanese patients with advanced STS, including 2 MFS patients, the ORR was 0% and the median PFS was 1.4 months [112].